The largest community of pharma leaders

TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–TROPION-Lung01 head-to-head phase 3 trial initiated to evaluate datopotamab deruxtecan versus docetaxel.

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles